部分厚度烧伤治疗选择:皮肤同种异体移植与局部银敷料的成本-效用分析
该研究采用决策树分析,比较皮肤同种异体移植与磺胺嘧啶银(SSD)及Mepilex Ag治疗20%总体表面积浅二度烧伤的成本-效用;异体移植增量成本分别为907.71美元和1257.86美元,增量QALY为0.011和0.016,增量成本效用比分别为84,189.29美元/QALY和79,684.63美元/QALY;在100,000美元/QALY支付意愿阈值下,异体移植对Mepilex Ag和SSD具有成本效用的概率分别为62.1%和64.9%。
要点
- 异体移植较Mepilex Ag和SSD的增量成本分别为907.71和1257.86美元。
- 异体移植较Mepilex Ag和SSD的增量QALY分别为0.011和0.016。
- 在100,000美元/QALY阈值下,异体移植成本有效的概率为62.1%(vs Mepilex Ag)和64.9%(vs SSD)。
核心结论
- 皮肤同种异体移植相比局部银敷料可获得更高的QALY,但成本也更高。
- 取决于支付意愿阈值,皮肤同种异体移植可能被视为部分厚度烧伤的成本有效治疗。
研究设计与样本
- 成本-效用分析,采用决策树分析比较皮肤同种异体移植与SSD及Mepilex Ag。
- 基础病例模型为20%总体表面积的浅二度烧伤。
- 效用值基于专家个人经验的意见,成本来源于2019年Medicare支付数据。
- 采用回滚法计算质量调整生命年(QALY),假设美国标准预期寿命。
- 进行了概率敏感性分析以评估模型稳健性。
主要发现
- 皮肤同种异体移植相对于Mepilex Ag的增量成本为907.71美元,相对于SSD的增量成本为1257.86美元。
- 皮肤同种异体移植相对于Mepilex Ag的增量QALY为0.011,相对于SSD的增量QALY为0.016。
- 皮肤同种异体移植 vs Mepilex Ag的增量成本效用比为84,189.29美元/QALY。
- 皮肤同种异体移植 vs SSD的增量成本效用比为79,684.63美元/QALY。
- 假设支付意愿阈值为100,000美元/QALY,概率敏感性分析显示皮肤同种异体移植相对于Mepilex Ag在62.1%的场景中具有成本效用,相对于SSD在64.9%的模拟中具有成本效用。
临床怎么用
- 在考虑支付意愿阈值的前提下,皮肤同种异体移植可作为部分厚度烧伤的一种成本有效治疗选择。
局限性
- 效用值基于专家个人经验的意见,而非患者报告或文献来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Partial thickness burns not undergoing surgical excision are treated with topical silver products including silver sulfadiazine (SSD) and Mepilex Ag. Skin allograft is a more costly alternative that acts as definitive wound coverage until autogenous epithelialization. Economic constraints and the movement toward value-based care demand cost and outcome justification prior to adopting more costly products. METHODS: A cost-utility analysis was performed comparing skin allograft to SSD and Mepilex Ag using decision tree analysis. The base case modeled a superficial partial thickness 20% total body surface area burn. Utilities were derived from expert opinion on the basis of personal experience. Costs were derived from 2019 Medicare payments. Quality adjusted life years were calculated using rollback method assuming standard life expectancies in the United States. Probabilistic sensitivity analysis was performed to asses model robustness. RESULTS: The incremental costs of skin allograft to Mepilex Ag and SSD were $907.71 and $1257.86, respectively. The incremental quality adjusted life year (QALY) gains from allograft over Mepilex Ag and SSD were 0.011 and 0.016. This yielded an incremental cost-utility ratio for allograft vs. Mepilex Ag of $84,189.29/QALY compared with an incremental cost-utility ratio of $79,684.63/QALY for allograft vs. SSD. Assuming willingness-to-pay thresholds of $100,000/QALY, probabilistic sensitivity analysis demonstrated that allograft was cost effective to Mepilex Ag in 62.1% of scenarios, and cost effective to SSD in 64.9% of simulations. CONCLUSION: Skin allograft showed greater QALYs compared with topical silver dressings at a higher cost. Depending on willingness-to-pay thresholds, skin allograft may be a considered a cost-effective treatment of partial-thickness burns.
引用
- Sheckter CC, Meyerkord NL, Sinskey YL, et al. The Optimal Treatment for Partial Thickness Burns: A Cost-Utility Analysis of Skin Allograft vs. Topical Silver Dressings. J Burn Care Res. 2020. PMID: 32043154. doi:10.1093/jbcr/iraa003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。